Product Reports Resources Pricing Login Book a demo

GLP

Food · South Korea · Founded 2016

Non-clinical testing services for chemical substances and biologics MoreLess

CentralBio is a South Korean non-clinical contract research organization (CRO) that provides safety and efficacy evaluation services. Founded in August 2016 by CEO Min Kwon, the company specializes in non-clinical trials for a diverse range of products including pharmaceuticals, health functional foods, cosmetics, chemical substances, and crop protection agents. Min Kwon previously co-founded AB Solution, a pesticide testing agency, in 2013. CentralBio was established to conduct GLP (Good Laboratory Practice) and other research testing.

The company operates as a B2B service provider, catering to pharmaceutical, biotech, and chemical companies that need to conduct safety and efficacy assessments for their products before human clinical trials. Its business model is based on providing commissioned testing services, which became increasingly crucial following the 2018 implementation of the Act on the Registration and Evaluation of Chemical Substances (K-REACH) in South Korea, mandating safety evaluations for all new chemical substances. CentralBio offers a comprehensive suite of services, including chemical hazard assessments, toxicity tests, and bioanalysis of clinical and non-clinical samples through its specialized "CentralLab". The company has secured numerous GLP certifications from regulatory bodies such as the Ministry of Food and Drug Safety and the Ministry of Environment.

Financially, CentralBio has demonstrated consistent growth, reporting revenues of KRW 9.9 billion in 2021. The company has successfully raised capital through venture funding, including a Series B round of KRW 11.2 billion in July 2022 from investors like Behigh Investment and IBK Capital to expand its facilities and operations. With its headquarters and advanced testing facilities located in Incheon, CentralBio planned an initial public offering (IPO) on the KOSDAQ market.

Keywords: non-clinical CRO, GLP testing, safety evaluation, efficacy testing, toxicology services, chemical hazard assessment, bioanalysis, crop protection agents, pharmaceutical development, cosmetics testing, drug discovery, contract research organization, K-REACH, preclinical studies, chemical registration, functional foods, medical devices, animal testing alternatives, bio-healthcare, substance evaluation

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

2 investors on GLP's cap table

Sourced from Dealroom's funding and investor records.

Series A 2 investors entered at this stage
IBK Capital
Bihai Investment

Global footprint

Where GLP has talent and traffic

Workforce by country
🇰🇷 South Korea HQ
Book a demo for the full country breakdown

Market sentiment

What the market is saying about GLP

An AI-synthesized read of the highest-engagement posts about GLP on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GLP on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.